SCHEMBL7711248

SCHEMBL7711248

CC1=C(N)Nc2cc(CN(Cc3cccc(F)c3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.37
HDAC1 Q13547 3/20 0.36
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TSPO P30536 1/20 0.33
NPC1 O15118 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
LPAR1 Q92633 1/20 0.33
GRM2 Q14416 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
LIPE Q05469 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708353 0.92 GRM2 (0.37) RIPK1HDAC1HDAC3HDAC2NCOR2
SCHEMBL7704910 0.91 HDAC1 (0.45) HDAC1HDAC3HDAC2NCOR2MEN1
SCHEMBL7711360 0.89 TRPM8 (0.36) HDAC1HDAC3HDAC2NCOR2MAPT
SCHEMBL7704902 0.89 RIPK1 (0.37) RIPK1HDAC1HDAC3HDAC2NCOR2
SCHEMBL7710867 0.88 ALDH1A1 (0.38) RIPK1HDAC1HDAC3HDAC2NCOR2
SCHEMBL7704872 0.88 HSD17B2 (0.38) HDAC1HDAC3HDAC2NCOR2MAPT
SCHEMBL7708189 0.88 HDAC3 (0.37) HDAC1HDAC3HDAC2NCOR2TP53
SCHEMBL7711366 0.88 HDAC1 (0.37) HDAC1HDAC3HDAC2NCOR2ALDH1A1
SCHEMBL7713369 0.86 HDAC1 (0.34) HDAC1HDAC3HDAC2NCOR2TP53
SCHEMBL7713360 0.86 ALDH1A1 (0.37) HDAC1HDAC3HDAC2NCOR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed